Alnylam Says Phase 1b Brezosiran Study Showed Dose-Dependent CSF Mutant Huntingtin Reductions, Up To 83% Individually, No Dose-Dependent Safety Signals; Pivotal Study Planned 2027 Pending Regulatory Alignment
- Initial Phase 1b results show mean reduction of cerebrospinal fluid mutant huntingtin of 60 to 64% at month 3 with individual reduction of up to 83% and encouraging safety and tolerability with potential for twice
Alnylam's medicine reduced a harmful protein in Huntington's patients by up to 83%. This early result looks safe and promising, which is why they plan bigger tests next.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.